Tebao Biotech

Tebao Biotech is a prominent Chinese biopharmaceutical company focused on the development and commercialization of innovative recombinant protein drugs. Founded in 1996 and headquartered in Xiamen, the company leverages its proprietary PEGylation technology platform to create long-acting biologics with improved therapeutic profiles. Its lead product, Pegbin (Peginterferon alfa-2b), has become a standard of care for chronic hepatitis B in China, supporting the country's goal of achieving a functional cure for the disease. Beyond infectious diseases, Tebao Biotech maintains a diverse portfolio and pipeline addressing oncology, endocrinology, and metabolic disorders. The company is listed on the Shanghai Stock Exchange's STAR Market and continues to expand its manufacturing capabilities to meet global standards.